Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael D Jain

Showing results (11-20 of 102) with videos related to

Pageof 11
Sort By:
Blood|March 29, 2023
How I treat refractory CRS and ICANS after CAR T-cell therapyMichael D Jain, Melody Smith, Nirali N Shah
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 1, 2022
Cellular therapy: Great promise, but at what cost?Matthew G Mei, Lisa Masucci, Michael D Jain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2026
Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic MalignanciesRawan G Faramand, Zhuoer Xie, Michael D Jain
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 28, 2025
Easy as ABC: Managing Toxicities of Antibody-Drug Conjugates, Bispecific Antibodies, and CAR T-Cell TherapiesMichael D Jain, Jeremy S Abramson, Stephen M Ansell
Nature Medicine|July 16, 2025
Noncanonical and mortality-defining toxicities of CAR T cell therapyKai Rejeski, Joshua A Hill, Saurabh Dahiya, et al.
Hematology/Oncology and Stem Cell Therapy|June 17, 2019
Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading modelsJulio C Chavez, Michael D Jain, Mohamed A Kharfan-Dabaja
Nature Reviews. Clinical Oncology|April 15, 2026
Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disordersAlaa Ali, Metin Ozdemirli, Mark P Hamilton, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society|January 5, 2002
High-resolution mapping of the Gli3 mutation extra-toes reveals a 51.5-kb deletionThomas M Maynard, Michael D Jain, Curtis W Balmer, et al.
Therapeutics and Clinical Risk Management|June 19, 2018
Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphomaMichael D Jain, Christina A Bachmeier, Vania H Phuoc, et al.
The Lancet. Haematology|May 11, 2024
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to managementKai Rejeski, Michael D Jain, Nirali N Shah, et al.
Pageof 11

Showing results (11-20 of 102) with videos related to

Sort By:
Pageof 11
Blood|March 29, 2023
How I treat refractory CRS and ICANS after CAR T-cell therapyMichael D Jain, Melody Smith, Nirali N Shah
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 1, 2022
Cellular therapy: Great promise, but at what cost?Matthew G Mei, Lisa Masucci, Michael D Jain
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2026
Long-Term Survivorship After Chimeric Antigen Receptor T-Cell Therapy for Hematologic MalignanciesRawan G Faramand, Zhuoer Xie, Michael D Jain
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|April 28, 2025
Easy as ABC: Managing Toxicities of Antibody-Drug Conjugates, Bispecific Antibodies, and CAR T-Cell TherapiesMichael D Jain, Jeremy S Abramson, Stephen M Ansell
Nature Medicine|July 16, 2025
Noncanonical and mortality-defining toxicities of CAR T cell therapyKai Rejeski, Joshua A Hill, Saurabh Dahiya, et al.
Hematology/Oncology and Stem Cell Therapy|June 17, 2019
Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-cell therapy: A comprehensive review of emerging grading modelsJulio C Chavez, Michael D Jain, Mohamed A Kharfan-Dabaja
Nature Reviews. Clinical Oncology|April 15, 2026
Spectrum, pathobiology, mechanistic insights and diagnostic challenges of post-CAR T cell therapy lymphoproliferative disordersAlaa Ali, Metin Ozdemirli, Mark P Hamilton, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society|January 5, 2002
High-resolution mapping of the Gli3 mutation extra-toes reveals a 51.5-kb deletionThomas M Maynard, Michael D Jain, Curtis W Balmer, et al.
Therapeutics and Clinical Risk Management|June 19, 2018
Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin's lymphomaMichael D Jain, Christina A Bachmeier, Vania H Phuoc, et al.
The Lancet. Haematology|May 11, 2024
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to managementKai Rejeski, Michael D Jain, Nirali N Shah, et al.
Pageof 11